Moving the Efficacy Needle With Immunotherapy in Melanoma

The CME was held in conjunction with the 2025 ASCO^® Annual Meeting in Chicago. It addresses challenges in delivering immunotherapy, enhances knowledge of current evidence and guidelines in cutaneous melanoma, sharpens skills for using immune-based options for patients with unresectable melanoma and helps learn how to select immunotherapy-based adjuvant and neoadjuvant therapy in resectable melanoma settings.

The program includes Hussein Tawbi, MD, PhD, Prof. Paolo Antonio Ascierto, MD, and Isabella C. Glitza Oliva, MD, PhD. It is provided by PeerView, in partnership with AIM at Melanoma Foundation. This program is for 1.5 CME/MOC/AAPA/IPCE credits.

CME credit: 1.5

When Anti-PD1 Therapy Fails: Could Oncolytic Immunotherapy Impact Outcomes in Advanced Melanoma?

The Why, What, Who, and How of Oncolytic Immunotherapies for Skin Cancer. This CME activity is led by experts in the field. Presented by Gino K. In, MD, MPH, University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California; Allison Betof Warner, MD, PhD, Stanford University, Stanford Cancer Center, Stanford, California; and Michael K. Wong, MD, PhD, FRCPC, Roswell Park Cancer Institute, Buffalo, New York. Provided by PeerVoice in partnership with AIM at Melanoma Foundation.

CME credit: 1.00

Expires December 2, 2025

Previous educational offering:

Pathways for Optimized Adjuvant Immunotherapy Strategies in Resectable Melanoma

Gain expert insight on optimizing the use of adjuvant immunotherapy for patients with resectable melanoma in this interactive, expert led CME/CNE/CPE-certified 1-hr workshop. Michael A. Davies, MD, PhD, Professor and Chair, Department of Melanoma Medical Oncology, Professor, at the University of Texas, MD Anderson Cancer Center, will provide this education. Provided by Clinical Care Options, LLC, in partnership with AIM at Melanoma Foundation.

Nurse Practitioners/Nurses: 1.00 Nursing contact hour.

NO LONGER AVAILABLE FOR CREDIT

Past educational offerings:

Stage IV Melanoma: Strategies to Support Shared Decision Making

With an expanded array of therapeutic options for Stage IV melanoma, clinicians must grapple with increased complexity for decision making. This multimedia, interactive activity, Stage IV Melanoma: Strategies to Support Shared Decision Making  uses cases to illustrate state-of-the art management of Stage IV melanoma. The activity also illustrates how to use the AIM at Melanoma Stage IV melanoma decision-making support tool Stage IV melanoma decision-making support tool and Patient Action Plans to support shared decision making. The esteemed faculty, Drs Anna Pavlick and Sunandana Chandra, also illustrate effective communication strategies and multidisciplinary approaches to provide streamlined care and consistent education and patient engagement across the oncology care team.

Past offerings (available for review, not credit):

CME/CE on BRAF/MEK Inhibitor Therapy for Melanoma

Join our esteemed faculty—Krista M. Rubin, RN, MS, FNP-BC, and Ryan J. Sullivan, MD—as they explore optimal incorporation of targeted therapy in melanoma. This case addresses BRAF testing, appropriate use of BRAF/MEK inhibitor therapy, the profiles of the 3 targeted therapy options, side-effect management, and adherence/pharmacologic considerations.

CME/CE on interdisciplinary care for management of complex irAEs.

JCO Oncology Practice (JCO OP) CME/CE/CPE supplement using cases to illustrate optimal interdisciplinary management of immune-related adverse events, Immuno-Oncology Essentials: Applications in Clinical Scenarios.

Melanoma Therapeutics and Side-Effect Management: Making a Difference from the Outset 

Click here to visit AIMatCancerCE.org, learn more, and view the complete accreditation information.

A new JADPRO CE supplement on the management of immune-related adverse events, Immuno-Oncology Therapy Essentials: Proactive Management of Immune-Related Adverse Events.

Supported by an independent educational grant from Merck & Co., Inc.

The newly launched site, AIMatCancerCE.org, a dedicated portal of continuing education initiatives in cancer, features this first activity on managing side effects associated with newer melanoma therapies.  Showcasing 5 cases representing patients at varied stages of melanoma as well as the range of newer melanoma therapeutic options, this highly interactive activity will assist you in incorporating the Care Step Pathways and other tools from the MNI in real-world clinical scenarios. This is a free activity offering AMA PRA Category 1 Credits™, Continuing Nursing Education contact hours, as well as pharmacotherapy contact hours for advanced practice registered nurses.